IR – Alligator Bioscience

2022-09-30

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

• ATOR-1017 demonstrated excellent safety and tolerability at doses up to 900 mg • Stable disease as best tumor response reconfirms previous ...

2022-09-192022-09-19

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. Lun ...

2022-09-14

Data from Phase 1b dose escalation part of the study shows that mitazalimab combined with mFOLFIRINOX is safe and well tolerated 900 µg/kg d ...

2022-09-06

Lund, Sweden, September 6, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives w ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-05-31

ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...

2022-05-09

Lund, Sweden, May 9, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Staffan Encrantz and Den ...

2022-05-05

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2022-04-27

Regulatory

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...